Abstract:
:Prognoses of persons with chronic lymphocytic leukemia (CLL) including time-to-therapy (TTT) and survival is heterogeneous. Risk factors and predictive scoring systems are mostly developed in persons of predominately European descent with CLL. Whether these systems accurately predict TTT and survival of Han Chinese with CLL is unknown. We interrogated clinical and laboratory data from 334 newly diagnosed, untreated Chinese CLL without treatment indication upon diagnosis to identify variables associated with TTT and develop a prognostic score. Binet stage, blood lymphocyte level, TP53 abnormality, unmutated IGHV, prior HBV, and EBV infections were independently associated with TTT in multivariate analyses. We constructed a prognostic score dividing subjects into cohorts with low, intermediate, and high risk from diagnosis to TTT. Median TTTs were 139 months (range, 85-189 months), 25 months (12-38 months), and 4 months (1-7 months; P-value for trend <0.001). We identified variables associated with TTT in Chinese with CLL with no treatment indication and developed a predictive model for survival. Some variables associated with TTT are similar to those of persons of predominately European descent, whereas others, such as HBV and/or EBV infections, operate in Chinese and Europeans but are not currently included in prognostic and predictive staging systems in persons of European descent. They should be investigated.
journal_name
Hematol Oncoljournal_title
Hematological oncologyauthors
Qin S,Fan L,Liang J,Gale R,Miao Y,Wu Y,Wang R,Yang H,Wu W,Xia Y,Wu J,Zhu H,Wang L,Xu W,Li Jdoi
10.1002/hon.2520subject
Has Abstractpub_date
2018-10-01 00:00:00pages
656-662issue
4eissn
0278-0232issn
1099-1069journal_volume
36pub_type
杂志文章abstract::The use of pomalidomide after lenalidomide and (or) bortezomib failure in patients with multiple myeloma is not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the effectiveness of pomalidomide after failure of lenalidomide and (or) bortezomib. We search...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2192
更新日期:2016-06-01 00:00:00
abstract::The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacit...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2646
更新日期:2019-10-01 00:00:00
abstract::Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within the last two decades. However, until recently, improvement in overall survival (OS) was only documented in younger, transplant-eligible patients. In this analysi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2205
更新日期:2016-12-01 00:00:00
abstract::The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...
journal_title:Hematological oncology
pub_type: 杂志文章,meta分析,评审
doi:10.1002/hon.2152
更新日期:2015-09-01 00:00:00
abstract::During the formation of the Philadelphia (Ph) chromosome, in the majority of chronic myelogenous leukemia (CML) patients, the chromosome 22 breakpoint is located in the major breakpoint cluster region of the BCR gene (M-bcr). Minor and micro breakpoint cluster regions (m-bcr with e1a2 transcript and micro-bcr with e19...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.822
更新日期:2007-09-01 00:00:00
abstract::Oral mucositis (OM) is one of the side effects of hematopoietic stem cell transplantation (HSCT), resulting in major morbidity. The aim of this study was to determine the cost-effectiveness of the introduction of a specialized oral care program including laser therapy in the care of patients receiving HSCT with regard...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2050
更新日期:2014-03-01 00:00:00
abstract::The elongation factor 1A proteins (eEF1A1/A2) are known to play a role in tumours. We previously found that a more basic isoform of eEF1A (MBI-eEF1A) is present in the cytoskeletal/nuclear-enriched extracts of CCRF-CEM T-lymphoblasts but not in those of normal lymphocytes. To obtain deeper knowledge about MBI-eEF1A bi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2022
更新日期:2013-06-01 00:00:00
abstract::Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Survival has improved over the last several decades, mainly because of the incorporation of the anti-CD20 antibody rituximab into preexisting or rediscovered agents. The disease has a relapsing and remitting pattern, coupled with a risk of transform...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2711
更新日期:2020-08-01 00:00:00
abstract::Adult T-cell leukemia-lymphoma (ATLL) is a distinct clinicopathologic entity etiologically linked to HTLV-I infection. We have identified five cases of retrovirus-associated ATLL among Hawaii-born first generation offspring (nisei) of migrant Japanese. Four patients were offspring of migrant Japanese (issei) who emigr...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070210
更新日期:1989-03-01 00:00:00
abstract::This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2515
更新日期:2018-10-01 00:00:00
abstract::Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2368
更新日期:2017-12-01 00:00:00
abstract::Dapsone is commonly used for pneumocystis carinii pneumonia (PCP) prophylaxis in immunocompromised patients. It has been used as an alternative therapy in the hematopoietic stem cell transplant (HSCT) setting in patients who can't tolerate trimethoprim-sulfamethoxazole. The Sulfone syndrome is not a well-known sequela...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.780
更新日期:2006-09-01 00:00:00
abstract::Acute myeloid leukaemia (AML) is a clinically aggressive disease with marked genetic heterogeneity. Cytogenetic abnormalities provide the basis for risk stratification into clinically favourable, intermediate, and unfavourable groups. There are additional genetic mutations, which further influence the prognosis of pat...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2279
更新日期:2017-09-01 00:00:00
abstract::Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed wi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2378
更新日期:2017-12-01 00:00:00
abstract:BACKGROUND:A subset of patients with non-Hodgkin's lymphoma (NHL) with clinical stage I or IE at presentation is left without other NHL localizations following surgery performed for diagnostic histology, and thus without any target lesion to judge the immediate effectiveness of immediately applied additional treatment ...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/(sici)1099-1069(199705)15:2<53::aid-hon598
更新日期:1997-05-01 00:00:00
abstract::The effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) on the cell cycle of murine leukemic cells (L 1210 cells) were compared with those of 1-beta-D-arabinofuranosylcytosine (ara-C), known to be effective for acute leukemia. In a cytokinetic study, a combination of Feulgen microcytofluorometry and triti...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900030106
更新日期:1985-01-01 00:00:00
abstract::The relationship between myeloblast-like cells and cluster-forming cells detected by growth in agar has been studied in 22 untreated patients with acute non-lymphocytic leukemia by means of comparing data for 3H-TdR labelling of myeloblast-like cells and 3H-TdR suiciding of cluster-forming cells. The fraction of myelo...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900020210
更新日期:1984-04-01 00:00:00
abstract::The acquired clonal disorder Polycythaemia Vera leads to increased erythropoiesis, myelopoiesis and megakaryopoeisis. These anomalies result in an increased incidence of thromboembolic events, transformation to acute leukaemia and myelofibrosis. Treatments which aim to reduce the event rate may increase anaemia but ma...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.809
更新日期:2007-06-01 00:00:00
abstract::Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2775
更新日期:2020-10-01 00:00:00
abstract::Mesenchymal stem cells (MSCs) are a subset of multifunctional stem cells with self-renewal and multidirectional differentiation properties that play a pivotal role in tumor progression. MSCs are reported to exert biological functions by secreting specialized vesicles, known as exosomes, with tumor cells. Exosomes part...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2793
更新日期:2020-08-27 00:00:00
abstract::This report summarizes a closed workshop cosponsored by the American Association for Cancer Research, the European School of Oncology, and the 15th-International Conference on Malignant Lymphoma to discuss critical open questions on liquid biopsy in lymphoid malignancies, develops a roadmap for their analytical and cl...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2704
更新日期:2020-02-01 00:00:00
abstract::Advanced-stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced-intensity conditioning (RIC) regimen, is a promising treatment for advanced-stage MF/SS. We performed RIC-HSCT in nine patients with advanced MF/SS...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2162
更新日期:2016-03-01 00:00:00
abstract::Multiple myeloma, which is a monoclonal plasma cell malignancy, still remains incurable despite recent progress in our understanding of this disorder. Adoptive immunotherapy of multiple myeloma using cytokine-induced killer cells is yielding promising results in clinical trials; however, some myeloma cells still evade...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2326
更新日期:2017-12-01 00:00:00
abstract::Twenty-three patients (16 adults) failing their first or subsequent (n = 8) intensive treatment for de novo acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia lymphoid blast phase (n = 2) were managed with protocol POG 8201, originally introduced in relapsed ALL of childhood. In this programme, a four-dru...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900100206
更新日期:1992-03-01 00:00:00
abstract::Reactivation of remote hepatitis B infection (RHBI) is an important cause of morbidity in hematopoietic cell transplant (HCT) patients. We analyzed the prevalence of RHBI in 205 patients who underwent HCT in our centre, serological events related to hepatitis B virus (HBV) reactivation and role of lamivudine prophylax...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2195
更新日期:2016-09-01 00:00:00
abstract::From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m2) was used in place of doxorubicin (50 mg/m2), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age was 41 years (range: 17 t...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/(sici)1099-1069(199809)16:3<117::aid-hon63
更新日期:1998-09-01 00:00:00
abstract::A new monoclonal antibody (MAB), IA61gG2a, has been derived from Balb/c mice after immunization with T-cell chronic lymphocytic leukemia (T-CLL). This monoclonal antibody, 1A6 was tested on normal human peripheral blood cells, leukemia patients' cells and leukemia-lymphoma cell lines. The results demonstrated that thi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070306
更新日期:1989-05-01 00:00:00
abstract::The glucose-6-phosphatase (G-6-Pase) enzyme cytochemical reaction was successfully applied on lymph node imprints, after introducing the appropriate modifications related to fixation and to composition of the substrate solutions. Using this method we studied the G-6-Pase cytochemical profile on lymph node imprint prep...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900040403
更新日期:1986-10-01 00:00:00
abstract::Twenty-five patients with either previously untreated advanced Hodgkin's disease (HD) or with relapsed disease were treated with an intensive weekly chemotherapy regimen (ChlOPhEPP-B) in which the myelosuppressive combinations of epirubicin and chlorambucil, and procarbazine and etoposide alternated at two-week interv...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.2900100604
更新日期:1992-11-01 00:00:00
abstract::Post-transplant lymphoproliferative disorders (PTLD) are a major problem in transplant medicine. So far, the insights into pathogenesis and potentially druggable pathways in PTLD remain scarce. We investigated a cohort of PTLD patients, consisting of both polymorphic (n = 3) and monomorphic (n = 19) B-cell lymphoproli...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2280
更新日期:2017-06-01 00:00:00